1. Netherlands Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
argenx SE

argenx SE

ARGX
argenx SEUS flagNASDAQ Global Select
871.96
USD
+25.77
- -
54.23BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.24
0.6
0.48
0.82
1.78
0.68
2.03
0.91
9.74
7.55
21.45
36.59
67.76
75.52
Basic EPS, GAAP
-0.54
-1.66
-1.06
-1.19
-1.37
-2.12
-4.69
-13.4
-7.99
-13.05
-5.16
13.92
21.08
24.12
Free Cash Flow per Basic Share
-0.59
-0.87
-0.99
0.54
-1.8
-1.73
2.72
-8.89
-14.26
-17.78
-8.12
-2.52
9.36
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-2.2
-5.51
-3.44
-3.94
-4.75
-5.28
-9.79
-21.72
-27.29
-38.67
-41.94
-26.14
-4.44
- -
Tangible Book Value per Share
1.91
8.06
2.59
3.54
16.81
17.12
29.4
33.18
46.26
48.52
69.48
88.83
115.03
- -
Basic Weighted Avg Shares
16
8
16
19
25
36
39
45
51
54
57
60
61
62
Sales/Revenue/Turnover
4
5
7
15
44
25
78
41
497
411
1,226
2,190
4,153
4,661
Operating Margin (%)
-232.69
-286.02
-227.68
-145.56
-62.97
-381.01
-255.04
-1,165.21
-72.37
-176.24
-34.3
-0.81
25.39
28.05
Depreciation Expense
- -
- -
- -
- -
1
1
2
4
6
104
111
18
28
- -
Net Income, GAAP
-8
-13
-17
-22
-34
-76
-181
-608
-408
-710
-295
833
1,292
1,489
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.91
Profit Margin (%)
-229.03
-274.6
-223.4
-145.27
-77.1
-310.22
-230.95
-1,475.29
-82.1
-172.76
-24.06
38.03
31.11
31.94
Working Capital
29
60
39
73
411
609
1,363
1,729
2,242
2,472
3,701
4,213
5,579
- -
LT Debt
- -
- -
- -
- -
- -
- -
5
6
8
9
15
33
36
- -
Total Equity
30
61
41
67
414
616
1,180
1,674
2,534
2,814
4,098
5,498
7,323
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-73.21
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
11
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
36
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
62
- -
Market Capitalization
45,122
51,447
45,067

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
6,899
- -
Cash, Cash Equivalents & STI
- -
4,440
- -
Accounts Receivable, Net
- -
1,490
- -
Inventories
- -
474
- -
Total Current Liabilities
- -
1,320
- -
Payables & Accruals
- -
695
- -
ST Debt
- -
11
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
94.21%
35.08%
33.19%
Free Cash Flow
-189.63%
-97.19%
-479.69%
Net Income, GAAP
23.92%
-68.95%
55.1%
Sales/Revenue/Turnover
187.2%
291.02%
89.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
401
478
573
738
2,190
2025
790
948
1,127
1,288
4,153
2026
1,298
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.04
- -
1.52
- -
13.92
2025
2.77
- -
5.61
- -
21.08
2026
5.9
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Karen Massey
Full Time Employees
1,863
Sector
Healthcare
Industry
Biotechnology
Address
Laarderhoogtweg 25 Amsterdam NH Netherlands 1101EB
IPO Date
May 18, 2017
CIK
0001697862
Website
argenx.com
Similar Companies
Sunmax Biotechnology Co., Ltd. (4728.TWO)
Kringle Pharma, Inc. (4884.T)
DICE Therapeutics, Inc. (DICE)
Laekna, Inc. (2105.HK)
Abivax S.A. (AAVXF)
TRACON Pharmaceuticals, Inc. (TCON)
Business
argenx SE, a commercial-stage global immunology company, develops and commercializes differentiated antibody-based therapies targeting severe autoimmune diseases using its proprietary Immunology Innovation Program and SIMPLE Antibody platform; its lead product VYVGART (efgartigimod) is an FcRn blocker approved for generalized myasthenia gravis in the United States, Europe, Japan, Israel, Canada and Mainland China, as well as for chronic inflammatory demyelinating polyneuropathy, with subcutaneous formulations including pre-filled syringes launched to enhance patient access and ongoing label expansions into broader myasthenia gravis populations such as seronegative, pediatric and ocular via studies like ADAPT-SERON, ADAPT-JR and ADAPT-OCULUS; the pipeline features advancing candidates like ARGX-213 targeting FcRn, ARGX-121 for IgA, ARGX-109 for IL-6 and ARGX-220 as a novel sweeping antibody, alongside earlier programs and out-licensed assets including LP0145 (ARGX-112) to LEO Pharma for atopic dermatitis, AGMB-101 (ARGX-114) to AgomAb Therapeutics for fibrotic diseases and ARGX-115 (ABBV-151) to AbbVie for oncology. argenx SE operates in key markets including the United States, Europe, Japan and Greater China through partnerships such as with Zai Lab; it was founded in 2008 in Ghent, Belgium by Tim van Hauwermeiren, Hans de Haard and Torsten Dreier, with headquarters in Amsterdam, Netherlands, and maintains subsidiaries like argenx BV in the Netherlands, argenx SAS in France and argenx UK Ltd. Recent developments include expansion of VYVGART into immune thrombocytopenia and multifocal motor neuropathy via registrational programs like ADVANCE and EMPASSION with topline data anticipated, autoinjector development for 2027 launch, four new pipeline nominations through the Immunology Innovation Program in 2025, sustained R&D investment supported by approximately EUR 2.6 billion in cash equivalents as of late 2024, and global commercial infrastructure growth alongside strategic collaborations leveraging technologies like Halozyme's subcutaneous delivery.

Company News

APIChatGPT

  • defenseworld.net

    Boston Common Asset Management LLC Takes Position in argenex SE $ARGX

  • seekingalpha.com

    Artisan Mid Cap Fund Q2 2026 Performance Review

  • businesswire.com

    Chai Discovery Enters Into Collaboration Agreement With argenx to Advance AI-Driven Immunology Breakthroughs

  • zacks.com

    Are Medical Stocks Lagging Argenx (ARGX) This Year?

  • zacks.com

    FTRE or ARGX: Which Is the Better Value Stock Right Now?

  • investors.com

    This Profitable Autoimmune Biotech Trades Near A High And A Buy Point

  • 247wallst.com

    Live Nasdaq Composite: Markets Kick Off H2 2026 on Cautious Note amid Chip Stock Profit Taking

  • benzinga.com

    Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study

  • investors.com

    Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?

  • seekingalpha.com

    argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript

  • marketbeat.com

    argenx Eyes More VYVGART Growth as Pipeline Catalysts Near

  • investors.com

    Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

  • zacks.com

    ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know

  • seekingalpha.com

    argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

  • zacks.com

    SRPT vs. ARGX: Which Stock Is the Better Value Option?

  • zacks.com

    Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?

  • marketbeat.com

    argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference

  • globenewswire.com

    argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026

  • globenewswire.com

    argenx to Host Myositis R&D Webinar on June 23, 2026

  • globenewswire.com

    argenx to Present at Upcoming Investor Conferences